- Investing Ideas
- Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Australian Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Mesoblast
Market Cap: AU$2.9b
Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.
MSB
AU$2.45
7D
3.8%
1Y
-0.8%
Aroa Biosurgery
Market Cap: AU$207.5m
Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.
ARX
AU$0.58
7D
-4.9%
1Y
-9.4%